Overview of Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its ...

Glucagon-like peptide-1 receptor agonists ( GLP -1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD.
Key Details About Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call

On top of this, sodium-glucose co-transporter 2 inhibitors along with finerenone showed an impressive ability to reduce the progression of kidney disease and cardiovascular events in diabetic patients with CKD. Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) can play a special role and could be a game changer in this field.
Clinical trials such as SUSTAIN-6, REWIND, and FLOW provide evidence of GLP-1 receptor agonists reducing albuminuria and attenuating estimated glomerular filtration rate decline in patients with diabetic chronic kidney disease .

Useful Notes on Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 ( GLP-1 ) receptor agonists are a promising therapeutic option for patients with diabetic kidney disease (DKD).
Abstract Semaglutide (Smg), a GLP-1 receptor agonist ( GLP -1RA), shows renal protective effects in patients with diabetic kidney disease (DKD). However, the exact underlying mechanism remains elusive. This study employs transcriptome sequencing and identifies β -Klotho (KLB) as the critical target responsible for the role of Smg in kidney ...

Overview of Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
This receptor distribution suggests that GLP-1 receptor agonists may contribute to kidney function. Emerging evidence supports the role of GLP-1 receptor agonists in chronic kidney disease (CKD), particularly for patients with diabetes. These agents may slow CKD progression by improving glycemic control, reducing albuminuria, and possibly protecting against glomerular damage through their anti ...
Although much attention is currently focused on the weight management potential of incretin-based medications, such as glucagon-like peptide-1 ( GLP-1 ) receptor agonists , there is also a growing focus on the effects in patients with chronic kidney disease (CKD). The US Food and Drug Administration approved the GLP-1 receptor agonist semaglutide to reduce kidney and cardiovascular risk in ...

Key Details About Glp 1 Receptor Agonists And Diabetic Kidney Disease A Call
Kidney Disease : Improving Global Outcomes (KDIGO) published its first Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) in 2020 and updated the guideline in 2022.1 These guidelines outlined a comprehensive, evidence-based approach to evaluating and treating people with diabetes and CKD to improve kidney and cardiovascular outcomes. The 2020 guideline was ...







Additionally, GLP-1 reduces glucagon secretion by islet α cells, slows gastric emptying, and reduces appetite through effects on the hypothalamus.1 GLP-1 receptor agonists ( GLP -1RAs) were therefore developed as drugs for the treatment of type 2 diabetes.